Monalizumab: inhibiting the novel immune checkpoint NKG2A

Hall, T. van; Andre, P.; Horowitz, A.; Ruan, D.F.; Borst, L.; Zerbib, R.; ... ; Vivier, E. (2019)

Article / Letter to editor

• Cancer immunotherapy
• CD8 T cells
• NK cells
• NKG2A
• Inhibitory immune receptor
• HLA-E
• Qa-1

• All authors: Hall, T. van; Andre, P.; Horowitz, A.; Ruan, D.F.; Borst, L.; Zerbib, R.; Narni-Mancinelli, E.; Burg, S.H. van der; Vivier, E.
• Date: 2019-10-17
• Journal: Journal for ImmunoTherapy of Cancer
• Volume: 7
• Issue: 1
• DOI: doi:10.1186/s40425-019-0761-3